131 related articles for article (PubMed ID: 16469759)
1. The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany.
Siebert U; Sroczynski G; Hillemanns P; Engel J; Stabenow R; Stegmaier C; Voigt K; Gibis B; Hölzel D; Goldie SJ
Eur J Public Health; 2006 Apr; 16(2):185-92. PubMed ID: 16469759
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of primary HPV screening for cervical cancer in Germany--a decision analysis.
Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
Eur J Cancer; 2011 Jul; 47(11):1633-46. PubMed ID: 21482103
[TBL] [Abstract][Full Text] [Related]
3. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process.
Leyden WA; Manos MM; Geiger AM; Weinmann S; Mouchawar J; Bischoff K; Yood MU; Gilbert J; Taplin SH
J Natl Cancer Inst; 2005 May; 97(9):675-83. PubMed ID: 15870438
[TBL] [Abstract][Full Text] [Related]
4. The German Coronary Artery Disease Risk Screening Model: development, validation, and application of a decision-analytic model for coronary artery disease prevention with statins.
Stollenwerk B; Gerber A; Lauterbach KW; Siebert U
Med Decis Making; 2009; 29(5):619-33. PubMed ID: 19773581
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range?
Anderson R; Haas M; Shanahan M
Aust N Z J Public Health; 2008 Feb; 32(1):43-52. PubMed ID: 18290913
[TBL] [Abstract][Full Text] [Related]
6. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden.
Andrae B; Kemetli L; Sparén P; Silfverdal L; Strander B; Ryd W; Dillner J; Törnberg S
J Natl Cancer Inst; 2008 May; 100(9):622-9. PubMed ID: 18445828
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong.
Kim JJ; Leung GM; Woo PP; Goldie SJ
J Public Health (Oxf); 2004 Jun; 26(2):130-7. PubMed ID: 15284314
[TBL] [Abstract][Full Text] [Related]
8. High-grade cervical abnormalities and screening intervals in New South Wales, Australia.
Schindeler S; Morrell S; Zuo Y; Baker D
J Med Screen; 2008; 15(1):36-43. PubMed ID: 18416954
[TBL] [Abstract][Full Text] [Related]
9. Clinical and cost implications of new technologies for cervical cancer screening: the impact of test sensitivity.
Hutchinson ML; Berger BM; Farber FL
Am J Manag Care; 2000 Jul; 6(7):766-80. PubMed ID: 11067374
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan.
Koong SL; Yen AM; Chen TH
J Med Screen; 2006; 13 Suppl 1():S44-7. PubMed ID: 17227642
[TBL] [Abstract][Full Text] [Related]
11. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
Schneider A; Schwarz TF; Hammerschmidt T; Siebert U
Med Klin (Munich); 2007 Jul; 102(7):515-23. PubMed ID: 17634869
[TBL] [Abstract][Full Text] [Related]
12. Effective cervical cytology screening programmes in middle-income countries: the Chilean experience.
Sepúlveda C; Prado R
Cancer Detect Prev; 2005; 29(5):405-11. PubMed ID: 16188399
[TBL] [Abstract][Full Text] [Related]
13. Cervical cancer screening in medically underserved California Latina and non-Latina women: effect of age and regularity of Pap testing.
Howell LP; Gurusinghe S; Tabnak F; Sciortino S
Cancer Detect Prev; 2009; 32(5-6):372-9. PubMed ID: 19264426
[TBL] [Abstract][Full Text] [Related]
14. Effect of an antepartum Pap smear on the coverage of a cervical cancer screening programme: a population-based prospective study.
Nygård M; Daltveit AK; Thoresen SO; Nygård JF
BMC Health Serv Res; 2007 Jan; 7():10. PubMed ID: 17244348
[TBL] [Abstract][Full Text] [Related]
15. Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain.
Gauthier A; Martín-Escudero V; Moore L; Ferko N; de Sanjosé S; Pérez-Escolano I; Catalá-López F; Ferrer E; Bosch FX
Eur J Public Health; 2008 Dec; 18(6):674-80. PubMed ID: 18641420
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of cervical cancer screening over cervical cancer mortality among Japanese women.
Aklimunnessa K; Mori M; Khan MM; Sakauchi F; Kubo T; Fujino Y; Suzuki S; Tokudome S; Tamakoshi A; ; Motohashi Y; Tsuji I; Nakamura Y; Iso H; Mikami H; Inaba Y; Hoshiyama Y; Suzuki H; Shimizu H; Toyoshima H; Wakai K; Ito Y; Hashimoto S; Kikuchi S; Koizumi A; Kawamura T; Watanabe Y; Miki T; Date C; Sakata K; Nose T; Hayakawa N; Yoshimura T; Shibata A; Okamoto N; Shino H; Ohno Y; Kitagawa T; Kuroki T; Tajima K
Jpn J Clin Oncol; 2006 Aug; 36(8):511-8. PubMed ID: 16844732
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening.
Bidus MA; Maxwell GL; Kulasingam S; Rose GS; Elkas JC; Chernofsky M; Myers ER
Obstet Gynecol; 2006 May; 107(5):997-1005. PubMed ID: 16648402
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of cervical cancer screening program at a rural community of South Africa.
Hoque M; Hoque E; Kader SB
East Afr J Public Health; 2008 Aug; 5(2):111-6. PubMed ID: 19024420
[TBL] [Abstract][Full Text] [Related]
19. A case-control study of the protective benefit of cervical screening against invasive cervical cancer in NSW women.
Yang B; Morrell S; Zuo Y; Roder D; Tracey E; Jelfs P
Cancer Causes Control; 2008 Aug; 19(6):569-76. PubMed ID: 18286380
[TBL] [Abstract][Full Text] [Related]
20. Addressing Taiwan's high incidence of cervical cancer: factors associated with the Nation's low compliance with Papanicolaou screening in Taiwan.
Liao CC; Wang HY; Lin RS; Hsieh CY; Sung FC
Public Health; 2006 Dec; 120(12):1170-6. PubMed ID: 17074376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
